Head and neck squamous cell carcinoma
HNSCC · Oncology · 2 drugs · 3 indications
Cancers of oral cavity, pharynx, and larynx.
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Petosemtamab | GMAB | LGR5xEGFR bispecific | Bispecific | IV | PHASE3 |
| Keytruda | MRK | PD-1 inhibitor | Antibody | IV | APPROVED |
Indications (3)
R/R head and neck squamous cell carcinoma
1L head and neck squamous cell carcinoma
Upcoming Catalysts
Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL
MRK2026
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN2)CLINICAL
GMABH2 2026
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN1)CLINICAL
GMABH2 2026
Keytruda - LOE PreparationCOMPETITIVE
MRKOngoing
Petosemtamab - HNSCC - BLA FilingREGULATORY
GMABH1 2027
Data from Supabase · Updated 2026-03-24